TY - JOUR AU - Gadwalkar, Arathi S. AU - K., Prabhakar AU - A., Raveesha AU - Ghungroo, Shaama PY - 2020/05/26 Y2 - 2024/03/29 TI - HbA1c as a prognostic indicator in prediabetics with acute coronary syndrome JF - International Journal of Research in Medical Sciences JA - Int J Res Med Sci VL - 8 IS - 6 SE - Original Research Articles DO - 10.18203/2320-6012.ijrms20202030 UR - https://www.msjonline.org/index.php/ijrms/article/view/8159 SP - 2004-2012 AB - <p class="abstract"><strong>Background:</strong> The role of HbA1C in predicting the outcomes of acute coronary syndrome remains controversial. Lesser is known about it in non-diabetic patients. Therefore authors conducted a study to seek association between the HbA1C levels and the clinical outcome in non-diabetic patients who presented with acute coronary syndrome. Objective of the study was to estimate HbA1C levels in population of prediabetics and non-diabetics and to document and correlate major adverse cardiac events in prediabetic and non-diabetics.</p><p class="abstract"><strong>Method:</strong> This case control study included consecutive patients (n=68) without known diabetes mellitus admitted with acute coronary syndrome (STEMI, NSTEMI, UA) at our hospital. HbA1c was measured on admission. The patients were divided into 2 groups according to their HbA1c level (group 1 HbA1c&lt;5.7%, group 2 HbA1c&gt;5.7%). The main outcome was MACE (major adverse cardiac events including cardiogenic shock, arrhythmia, heart failure).</p><p class="abstract"><strong>Results:</strong> There was no significant difference between baseline characteristics of both groups but complications were seen in higher number cases with HbA1c &gt;5.7%. No significant difference in mortality was found. On analysis HbA1c &gt;5.7% was found to be an independent predictor of MACE.</p><p class="abstract"><strong>Conclusion:</strong> HbA1C is a predictor of major adverse cardiac events. Measurement of HbA1C levels may improve risk assessment in such patients presenting with ACS.</p> ER -